Use of magnetic resonance imaging in pharmacogenomics

British Journal of Clinical Pharmacology

Volumn 77, Issue 4, 2014, Pages 684-694

  Viviani, Roberto ^a,b   Lehmann, Marie Louise ^c,d   Stingl, Julia C ^c,d  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

neuroleptics; perfusion imaging; pharmacogenetic imaging

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ARTICLE; BIOAVAILABILITY; COGNITION; DRUG BIOAVAILABILITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; IN VIVO STUDY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOGENOMICS; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCINTIGRAPHY; BRAIN; DRUG EFFECTS; DRUG INACTIVATION; FUNCTIONAL NEUROIMAGING; GENETICS; PHARMACOGENETICS; PROCEDURES; PSYCHOMOTOR PERFORMANCE; TRENDS; VASCULARIZATION;

BRAIN; COGNITION; DOPAMINE AGONISTS; FUNCTIONAL NEUROIMAGING; HUMANS; INACTIVATION, METABOLIC; MAGNETIC RESONANCE IMAGING; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSYCHOMOTOR PERFORMANCE;

EID: 84897889479     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12197     Document Type: Article

References (112)

1. Kirchheiner J, Nickchen K, Bauer M, Wong M-L, Licinio J, Roots I, Brockmöller J,. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-473.
2. Kirchheiner J, Seeringer A, Viviani R,. Pharmacogenetics in psychiatry. A useful clinical tool or wishful thinking for the future? Curr Pharm Des 2010; 16: 136-144.
3. Leslie RA, James MF,. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol Sci 2000; 21: 314-318.
4. Honey GD, Bullmore E,. Human pharmacological MRI. Trends Pharmacol Sci 2004; 25: 366-374.
5. Hariri AR, Drabant EM, Weinberger DR,. Imaging genetics: perspectives from studies of genetically driven variation in serotonin functional and corticolimbic affective processing. Biol Psychiatry 2006; 59: 888-897.
6. Meyer-Lindenberg A, Weinberger DR,. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nature Rev Neurosci 2006; 7: 818-827.
7. Siebner HR, Callicott JH, Sommer T, Mattay VS,. From the genome to the phenome and back: linking genes with human brain function and structure using genetically informed neuroimaging. Neurosci 2009; 164: 1-6.
8. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anaesthetised albino rat. J Neurochem 1977; 28: 897-916.
9. Matthews PM, Honey GD, Bullmore ET,. Applications of fMRI in translational medicine and clinical practice. Nature Rev Neurosci 2006; 7: 732-744.
10. Glahn DC, Thompson PM, Blangero J,. Neuroimaging endophenotypes: strategies for finding genes influencing brain structure and function. Hum Br Mapping 2007; 28: 488-501.
11. Gottesmann II, Gould TD,. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-645.
12. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, Sanislow C, Wang P,. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010; 167: 748-751.
13. Posner MI, Raichle ME,. Images of the Mind. New York: Freeman, 1994.
14. Wise RG, Rogers R, Painter D, Bantick S, Ploghaus A, Williams P, Rapeport G, Tracey I,. Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentalin. NeuroImage 2002; 16: 999-1014.
15. Poldrack RA,. Can cognitive processes be inferred from neuroimaging data? Trends Cogn Sci 2006; 10: 59-63.
16. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, Goodman JM, Kantor HL, Gastfriend DR, Riorden JP, Mathew RT, Rosen BR, Hyman SE,. Acute effects of cocaine on human brain activity and emotion. Neuron 1997; 19: 591-611.
17. Raichle ME, Fiez JA, Videen TO, MacLeod AMK, Pardo JV, Fox PT, Petersen SE,. Practice-related changes in human brain functional anatomy during nonmotor learning. Cereb Cortex 1994; 4: 8-26.
18. Grill-Spector K, Henson R, Martin A,. Repetition and the brain: neural models of stimulus-specific effects. Trends Cogn Sci 2006; 10: 14-23.
19. Logothetis MK,. The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. Phil Trans R Soc B 2002; 357: 1003-1037.
20. Ogawa S, Tank DW, Menon R, Ellermann JM, Kim SG, Merkle H, Ugurbil K,. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci U S A 1992; 89: 5951-5955.
21. Kwong KK, Belliveau JW, Chesler DA, Goldberg IE, Weisskoff RM, Poncelet BP, Kennedy DN, Hoppel BE, Cohen MS, Turner R, Cheng HM, Brady TJ, Rosen BR,. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A 1992; 89: 5675-5679.
22. Sokoloff L,. Local cerebral energy metabolism: its relationship to local functional activity and blood flow. Cerebral Vascular Smooth Muscle and its Control 1978; vol. 56, Ciba Foundation Symposium.
23. Ogawa S, Lee TM, Kay AR, Tank DW,. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci U S A 1990; 87: 9868-9872.
24. Williams DS, Detre JA, Leigh JS, Koretsky AP,. Magnetic resonance imaging of perfusion using spin-inversion of arterial water. Proc Natl Acad Sci U S A 1992; 89: 212-216.
25. Pizzagalli DA,. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011; 36: 183-206.
26. Wang JJ, Aguirre GK, Kimberg DY, Roc AC, Li L, Detre JA,. Arterial spin labeling perfusion fMRI with very low task frequency. Magn Reson Med 2003; 49: 796-802.
27. Wang DJJ, Chen Y, Fernández-Sara MA, Detre JA,. Potential and challenges for arterial spin labelling in pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 2011; 337: 359-366.
28. Wise RG, Preston C,. What is the value of human FMRI in CNS drug development? Drug Discov Today 2010; 15: 973-980.
29. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA,. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 1996; 153: 41-49.
30. Miller DD, Rezai K, Alliger R, Andreasen NC,. The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: assessment with Technetium-99m Hexamethyl-Propyleneamine Oxime single photon emission computer tomography. Biol Psychiatry 1997; 41: 550-559.
31. Fernández-Seara MA, Aznárez-Sanado M, Mengual E, Irigoyen J, Heukamp F, Pastor MA,. Effects on resting state cerebral blood flow and functional connectivity induced by metoclopramide: a perfusion MRI study in healthy volunteers. Br J Pharmacol 2011; 163: 1639-1652.
32. Handley R, Zelaya FO, Reinders AATS, Reis Marques T, Mehta MA, O'Gorman R, Alsop DC, Taylor H, Johnston A, Williams S, McGuire P, Pariante CM, Kapur S, Dazzan P,. Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. Hum Br Mapping 2013; 34: 272-282.
33. Viviani R, Graf H, Wiegers M, Abler B,. Effects of amisulpride on human resting cerebral perfusion. Psychopharmacol (Berl) 2013. doi: 10.1007/s00213-013-3091-z. (epub ahead of print).
34. Miller DD, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, Hichwa RD,. Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biol Psychiatry 2001; 49: 704-715.
35. Viviani R, Abler B, Seeringer A, Stingl JC,. Effect of paroxetine and bupropion on human resting brain perfusion: an arterial spin labelling study. NeuroImage 2012; 61: 773-779.
36. Choi JK, Chen YI, Hamel E, Jenkins BG,. Brain hemodynamic changes mediated by dopamine receptors: role of the cerebral microvasculature in dopamine-mediated neurovascular coupling. NeuroImage 2006; 30: 700-712.
37. Hamel E,. Perivascular nerves and the regulation of cerebrovascular tone. J Appl Physiol 2006; 100: 1059-1064.
38. Schwarz AJ, Zocchi A, Reese T, Gozzi A, Garzotti M, Varnier G, Curcuruto O, Sartori I, Girlanda E, Biscaro B, Crestan V, Bertani S, Heidbreder C, Bifone A,. Concurrent pharmacological MRI and in situ microdialysis of cocaine reveal a complex relationship between the central hemodynamic response and local dopamine concentration. NeuroImage 2004; 23: 296-304.
39. Jenkins BG,. Pharmacologic magnetic resonance imaging (phMRI): imaging drug action in the brain. NeuroImage 2012; 62: 1072-1085.
40. Chen YCI, Galpern WR, Brownell AL, Matthews RT, Bogdanov M, Isacson O, Keltner JR, Beal MF, Rosen BR, Jenkins BG,. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 1997; 38: 389-398.
41. Chen YC, Choi JK, Andersen SL, Rosen BR, Jenkins BG,. Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging. Psychopharmacol (Berl) 2005; 180: 705-715.
42. Miller DD, Andreasen NC, O'Leary DS, Rezai K, Watkins L, Boles Ponto LL, Hichwa RD,. Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography. Neuropsychopharmacology 1997; 17: 230-240.
43. Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Tamminga CA,. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol Psychiatry 2003; 53: 601-608.
44. Biswal BB, Mennes M, Zuo XN, Gohel S, Kelly C, Smith SM, Beckmann CF, Adelstein JS, Buckner RL, Colcombe S, Dogonowski AM, Ernst M, Fair D, Hampson M, Hoptman MJ, Hyde JS, Kiviniemi VJ, Kötter R, Li SJ, Lin CP, Lowe MJ, Mackay C, Madden DJ, Madsen KH, Margulies DS, Mayberg HS, McMahon K, Monk CS, Mostofsky SH, Nagel BJ, Pekar JJ, Peltier SJ, Petersen SE, Riedl V, Rombouts SARB, Rypma B, Schlaggar BL, Schmidt S, Seidler RS, Siegle GJ, Sorg C, Teng GJ, Veijola J, Villringer A, Walter M, Wang L, Weng XC, Whitfield-Gabrieli S, Williamson P, Windischberger C, Zang YF, Zhang HY, Castellanos FX, Milham MP,. Toward discovery science of human brain function. Proc Natl Acad Sci U S A 2010; 107: 4734-4739.
45. Biswal BB, Yetkin FZ, Haughton VM, Hyde JS,. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med 1995; 34: 537-541.
46. Fransson P,. How default is the default mode of brain function? Further evidence from intrinsic BOLD signal fluctuations. Neuropsychologia 2006; 44: 2836-2845.
47. Kiviniemi V, Jauhiainen J, Tervonen O, Pääkkö E, Oikarinen J, Vainionpää V, Ranrala H, Biswal B,. Slow vasomotor fluctuation in the fMRI of the anesthetized child brain. Magn Reson Med 2000; 44: 378-383.
48. Kelly C, de Zubicaray G, Di Martino A, Copland DA, Reiss PT, Klein DF, Castellanos FX, Milham MP, McMahon K,. L-Dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study. J Neurosci 2009; 29: 7364-7378.
49. Li SJ, Biswal B, Li Z, Risinger R, Rainey C, Cho JK, Salmeron BJ, Stein EA,. Cocaine adminstration decreases functional connectivity in human primary visual and motor cortex as detected by functional MRI. Magn Reson Med 2000; 43: 45-51.
50. Greicius MD, Kiviniemi V, Tervonen O, Vainionpää V, Alahuta S, Reiss AL, Menon V,. Persistent default-mode network connectivity during light sedation. Hum Br Mapping 2008; 29: 839-847.
51. Cole DM, Beckmann CF, Long CJ, Matthews PM, Durcan MJ, Beaver JD,. Nicotine replacement in abstinent smokers improves cognitive withdrawal symptoms with modulation of resting brain network dynamics. NeuroImage 2010; 52: 590-599.
52. McCabe C, Mishor Z,. Antidepressant medications reduce subcortical-cortical resting-state functional connectivity in healthy volunteers. NeuroImage 2011; 57: 1317-1323.
53. Stamatakis EA, Adapa RM, Absalom AR, Menon DK,. Changes in resting neural connectivity during propofol sedation. PLoS ONE 2011; 5: e14224.
54. Sambataro F, Blasi G, Fazio L, Caforio G, Taurisano P, Romano R, Di Giorgio A, Gelao B, Lo Bianco L, Papazacharias A, Popolizio T, Nardini M, Bertolino A,. Treatment with olanzapine is associated with modulation of the default mode network in patients with schizophrenia. Neuropsychopharmacology 2010; 35: 904-912.
55. 158met in healthy young adults. J Neurosci 2010; 30: 64-69.
56. Tost H, Bilek E, Meyer-Lindenberg A,. Brain connectivity in psychiatric imaging genetics. NeuroImage 2012; 62: 2250-2260.
57. Viviani R, Messina I, Walter M,. Resting state functional connectivity in perfusion imaging: correlation maps with BOLD connectivity and resting state perfusion. PLoS ONE 2011; 6: e27050.
58. Bifone A, Gozzi A, Schwarz AJ,. Functional connectivity in the rat brain: a complex network approach. Magn Res Imaging 2010; 28: 1200-1209.
59. Kuschinsky W, Suda S, Bünger R, Yaffe S, Sokoloff L,. The effects of intravenous norepinephrine on the local coupling between glucose utilization and blood flow in the rat brain. Pflugers Arch 1983; 398: 134-138.
60. Mulderinck TA, Gitelman DR, Marsel Mesulam M, Parrish TB,. On the use of caffeine as a contrast booster for BOLD fMRI studies. NeuroImage 2002; 15: 37-44.
61. Addicott MA, Yang LL, Peiffer AM, Burnett LR, Burdette JH, Chen MY, Hyasaka S, Kraft RA, Maldjian JA, Laurienti PI,. The effect of daily caffeine use on cerebral blood flow: how much caffeine can we tolerate? Hum Brain Mapp 2009; 30: 3102-3114.
62. Chen Y, Parrish TB,. Caffeine dose effect on activation-induced BOLD and CBF responses. NeuroImage 2009; 46: 577-583.
63. Lawrence K, Ye FQ, Lewise BK, Frank JA, McLaughlin AC,. Measuring the effects of indomethacin on changes in cerebral oxidative metabolism and cerebral blood flow during sensorimotor activation. Magn Reson Med 2003; 50: 99-106.
64. Arthurs PJ, Stephenson CME, Rice K, Lupson VC, Spiegelhalter DJ, Boniface SJ, Bullmore ET,. Dopaminergic effects on electrophysiological and functional MRI measures of human cortical stimulus-response power laws. NeuroImage 2004; 21: 540-546.
65. Cohen Z, Bonvento G, Lacombe P, Hamel E,. Serotonin in the regulation of brain microcirculation. Prog Neurobiol 1996; 50: 335-362.
66. Chen Y, Wan HI, O'Reardon JP, Wang DJJ, Wang Z, Korczykowski M, Detre JA,. Quantification of cerebral blood flow as biomarker of drug effect: arterial spin labeling phMRI after a single dose of oral citalopram. Clin Pharmacol Ther 2011; 89: 251-258.
67. Cohen ER, Ugurbil K, Kim SG,. Effect of basal conditions on the magnitude and dynamics of the blood oxygenation level-dependent fMRI response. J Cereb Blood Flow Metab 2002; 22: 1042-1053.
68. Hyder F, Rothman DL, Shulman RG,. Total neuroenergetics support localized brain activity: implications for the interpretation of fMRI. Proc Natl Acad Sci U S A 2002; 99: 10771-10776.
69. Li A, Gong L, Xu F,. Brain-state-independent neural representation of peripheral stimulation in rat olfactory bulb. Proc Natl Acad Sci U S A 2011; 108: 5087-5092.
70. Aguirre GK, Detre JA, Zarahn E, Alsop DC,. Experimental design and the relative sensitivity of BOLD and perfusion fMRI. NeuroImage 2002; 15: 488-500.
71. Rabl U, Scharinger C, Müller M, Pezawas L,. Imaging genetics: implications for research on variable antidepressant drug response. Expert Rev Clin Pharmacol 2010; 3: 471-489.
72. 158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 2003; 100: 6186-6191.
73. American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41: (Suppl. 2): 26S-49S.
74. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW,. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 2000; 20: RC65.
75. Mattay VS, Callicott JH, Bertolino A, Heaton I, Frank JA, Coppola R, Berman KF, Goldberg TE, Weinberger DR,. Effects of dextroamphetamine on cognitive performance and cortical activation. NeuroImage 2000; 12: 268-275.
76. 108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001; 98: 6917-6922.
77. Owen AM, McMillan K, Laird AR, Bullmore E,. N-Back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum Brain Mapp 2005; 25: 46-59.
78. 108/158 met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004; 161: 1798-1805.
79. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, Lee MLT, Xiao T, Papp A, Wang D, Sadée W,. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci U S A 2007; 104: 20552-20557.
80. Freyberg Z, Ferrando SJ, Javitch JA,. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 2010; 167: 388-396.
81. Datta SR, Brunet A, Greenberg ME,. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-2927.
82. Bertolino A, Fazio L, Caforio G, Blasi G, Rampino A, Romano R, Di Giorgio A, Taurisano P, Papp A, Pinsonneault J, Wang D, Nardini M, Popolizio T, Sadée W,. Functional variants of the dopamine receptor D2 gene modulate profronto-striatal phenotypes in schizophrenia. Brain 2009; 132: 417-425.
83. Tan HY, Nicodemus KK, Chen Q, Li Z, Brooke JK, Honea R, Kolachana BS, Straub RE, Meyer-Lindenberg A, Sei Y, Mattay VS, Callicott JH, Weinberger DR,. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest 2008; 118: 2200-2208.
84. Blasi G, Napolitano F, Ursini G, Tausrisano P, Romano R, Caforio G, Fazio L, Gelao B, Di Giorgio A, Iacovelli L, Sinibaldi L, Popolizio T, Usiello A, Bertolino A,. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci U S A 2011; 108: 1158-1163.
85. Tan HY, Chen AG, Kolachana B, Apud JA, Mattay VS, Callicott JH, Chen Q, Weinberger DR,. Effective connectivity of AKT1-mediated dopaminergic working memory networks and pharmacogenetics of anti-dopaminergic treatment. Brain 2012; 135: 1436-1445.
86. Koepsell H, Lips K, Volk C,. Polyspecific organic cation transporters: structure, functions, physiological roles, and biopharmaceutical implications. Pharm Res 2007; 24: 1227-1251.
87. Haenisch B, Drescher E, Thiemer L, Xin H, Giros B, Gautron S, Bönisch H,. Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 1017-1023.
88. Bacq A, Balasse L, Biala G, Guiard B, Gardier AM, Schinkel A, Louis F, Vialou V, Martres MP, Chevarin C, Hamon M, Giros B, Gautron S,. Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Mol Psychiatry 2012; 17: 926-939.
89. Bloom AS, Hoffmann RG, Fuller SA, Pankiewicz J, Harsch HH, Stein EA,. Determination of drug-induced changes in functional MRI signal using a pharmacokinetic model. Hum Brain Mapp 1999; 8: 235-244.
90. Nordin LE, Li TQ, Brogren J, Johansson P, Sjögren N, Hannesdottir K, Björk C, Segerdahl M, Wang DJJ, Julin P,. Cortical responses to amphetamine exposure by pCASL MRI and pharmacokinetic/pharmacodynamic dose modeling. NeuroImage 2013; 68: 75-82.
91. Schouw MLJ, Kaag AM, Caan MWA, Hejtel DFR, Majoie CBLM, Nederveen AJ, Booij J, Reneman L,. Mapping the hemodynamic response in human subjects to a dopaminergic challenge with dextroamphetamine using ASL-based pharmacological MRI. NeuroImage 2013; 72: 1-9.
92. Kapur S, Zipursky R, Jones C, Remington G, Houle S,. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514-520.
93. Matthews PM, Rabiner I, Gunn R,. Non-invasive imaging in experimental medicine for drug development. Curr Opin Pharmacol 2011; 11: 5101-5107.
94. Nebert DW,. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Med Hum Genet 1997; 60: 265-271.
95. Ferguson CS, Tyndale RF,. Cytochrome P450 enzymes in the brain: emerging evidence for biological significance. Trends Pharmacol Sci 2011; 32: 798-14.
96. Stingl JC, Brockmöller J, Viviani R,. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry 2013; 18: 273-287.
97. Miksys S, Tyndale RF,. Cytochrome P450-mediated drug metabolism in the brain. J Psychiatry Neurosci 2012; 37: 120-133.
98. Persson A, Sim SC, Virding S, Onishchenko N, Schulte G, Ingelman-Sundberg M,. Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene. Mol Psychiatry 2013. (in press).
99. Mann A, Tyndale RF,. Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells. Mol Dev Neurosci 2010; 31: 1185-1193.
100. Sim SC, Nordin L, Andersson TML, Virding S, Olsson M, Pedersen NL, Ingelman-Sundberg M,. Association between CYP2C19 polymorphism and depressive symptoms. Am J Med Genet (Neuropsychiatr Genet) 2010; 153B: 1160-1166.
101. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C,. Influence of cytochrome P450 polymorphism on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526.
102. Kirchheiner J, Seeringer A, Godoy AL, Maier C, Beschoner P, Sim EJ, Viviani R,. CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol Psychiatry 2011; 16: 333-341.
103. Stingl JC, Esslinger C, Tost H, Bilek E, Kirsch P, Ohmle B, Viviani R, Walter H, Rietschel M, Meyer-Lindenberg A,. Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans. NeuroImage 2011; 59: 2818-2823.
104. Tan HY, Chen AG, Chen Q, Browne LB, Verchinski B, Kolachana B, Zhang F, Apud J, Callicott JH, Mattay VS, Weinberger DR,. Epistatic interactions of AKT1 on human medial temporal lobe biology and pharmacogenetic implications. Mol Psychiatry 2012; 17: 1007-1016.
105. Hahn T, Heinzel S, Plichta MM, Reif A, Lesch KP, Fallgatter AJ,. Neurovascular coupling in the human visual cortex is modulated by cyclooxygenase-1 (COX-1) gene variant. Cereb Cortex 2011; 21: 1659-1666.
106. Wang Z, Ray R, Faith M, Tang K, Wileyto EP, Detre JA, Lerman C,. Nicotine abstinence-induced cerebral blood flow changes by genotype. Neurosci Lett 2008; 438: 272-280.
107. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, Alce G, Iudicello JE, Akbar N, Egan MF, Goldberg TE, Weinberger DR,. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007; 32: 1011-1020.
108. Jacobsen LK, Pugh KR, Mencl WE, Gelernter J,. C957T polymorphism of the dopamine D2 receptor gene modulates the effect of nicotine on working memory performance and cortical processing efficiency. Psychopharmacol (Berl) 2006; 188: 530-540.
109. Loughead J, Wileyto EP, Valdez JN, Sanborn P, Tang K, Strasser AA, Ruparel K, Ray R, Gur RC, Lerman C,. Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype. Mol Psychiatry 2009; 14: 820-826.
110. Kirsch P, Reuter M, Mier D, Lonsdorf T, Stark R, Gallhofer B, Vaitl D, Hennig J,. Imaging gene-substance interactions: the effect of the DRD2 TaqlA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett 2006; 405: 196-201.
111. Cohen MX, Krohn-Grimberghe A, Elger CE, Weber B,. Dopamine gene predicts the brain's response to dopaminergic drug. Eur J Neurosci 2007; 26: 3652-3660.
112. Domschke K, Dannlowski U, Ohrmann P, Lawford B, Bauer J, Kugel H, Heindel W, Young R, Morris P, Arolt V, Deckert J, Suslow T, Baune BT,. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 2008; 18: 751-759.